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Abstract
Introduction: Sepsis has been identified as a risk factor for human cytomegalovirus (CMV) reactivation in critically
ill patients. However, the contribution of CMV reactivation on morbidity and mortality is still controversial.
Therefore, we analyzed the incidence and impact of CMV reactivation on outcome in patients with severe sepsis.
Methods: In a prospective longitudinal double-blinded observational study, 97 adult nonimmunosuppressed CMV-
seropositive patients with new onset of severe sepsis were included. Leukocytes, plasma and tracheal secretions
were examined weekly for CMV-DNA by PCR. Tracheal secretions were additionally tested for HSV (Herpes Simplex
Virus)-DNA. The influence of CMV-reactivation on the endpoints was analysed by Cox proportional-hazard
regression analysis. Time-dependency was evaluated by landmark analysis.
Results: Six out 97 died and five were discharged from the hospital within 72 hours and were excluded of the
analysis. CMV reactivation occurred in 35 of the 86 (40.69%) analysed patients. HSV infection occurred in 23 of the
35 (65.7%) CMV reactivators. In 10 patients CMV-plasma-DNAemia appeared with a DNA-content below 600 copies/
ml in four cases and a peak amount of 2,830 copies/ml on average. In patients with and without CMV reactivation
mortality rates were similar (37.1% vs. 35.3%, P = 0.861), respectively. However, in the multivariate COX regression
analyses CMV reactivation was independently associated with increased length of stay in the ICU (30.0, interquartile
range 14 to 48 vs. 12.0, interquartile range 7 to 19 days; HR (hazard ratio) 3.365; 95% CI (confidence interval) 1.233
to 9.183, P = 0.018) and in the hospital (33.0, interquartile range 24 to 62 vs. 16.0, interquartile range 10 to 24 days,
HR 3.3, 95% CI 1.78 to 6.25, P < 0.001) as well as prolonged mechanical ventilation (22.0, interquartile range 6 to 36
vs. 7.5, interquartile range 5 to 15.5 days; HR 2.6,CI 95% 1.39 to 4.94; P < 0.001) and impaired pulmonary gas
exchange (six days, interquartile range 1 to 17, vs. three, interquartile range 1 to 7, days in reactivators vs. non-
reactivators, P = 0.038). HSV reactivation proved not to be a risk factor for these adverse effects.
Conclusions: These data indicate an independent correlation between CMV reactivation and increased morbidity
in the well-defined group of nonimmunosuppressed patients with severe sepsis, but CMV reactivation had no
impact on mortality in this group with low CMV-DNA plasma levels. Thus, the potential harms and benefits of
antiviral treatment have to be weighed cautiously in patients with severe sepsis or septic shock.
Introduction
Human cytomegalovirus (CMV) is widely recognized as
the most serious viral pathogen in immunosuppressed
patients, such as solid organ transplant recipients or
those with malignant haematologic disorders or human
immunodeficiency virus (HIV) infection [1-6]. Like other
herpesviruses, CMV persists in the host after primary
infection, usually remaining in a latent state for the rest
of the host’s life [2]. Disturbances in the balance between
the host`s immune defenses and the non-active virus are
thought to trigger CMV reactivation, which may result in
CMV disease being associated with high morbidity and
mortality in immunosuppressed patients [2,7].
Generally, critically ill patients in the intensive care
unit (ICU) without exogenous immunosuppression are
not thought to be endangered by CMV reactivation.
However, in the last 10 years CMV reactivation rates
close to those found after kidney transplantation have
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although the typical mechanisms of immunosuppression
were absent [8-14]. In addition, there is a growing body
of evidence that not only CMV but also herpes simplex
virus (HSV) infections might have been considerably
underestimated in critically ill patients [11,15]. The reac-
tivation of both viruses is frequently observed in the
respiratory tract, but there are few systematic studies
investigating the reactivation of either CMV or HSV in
respiratory tract specimens [11,16,17].
Single studies in different types of various ICU popu-
lations suggest that CMV reactivation might adversely
affect the outcome of critically ill CMV-seropositive
patients, independently of the occurrence of CMV dis-
ease, and in a similar fashion HSV infections might have
negative effects on intensive care patients [9,13,17,18].
Bacterial sepsis has been identified as an independent
risk factor for CMV reactivation in the heterogeneous
population of critically ill patients [8,9]. Therefore, the
question arises whether CMV infection contributes to
increased morbidity and mortality to an extent warrant-
ing antiviral strategies in the risk group of patients with
severe sepsis. To our knowledge, until now only one pro-
spective study has addressed this issue in men [16], but
statistical analysis could not be performed due to the lim-
ited collective of only 25 patients. Moreover, the role of
coinfection with HSV in this context still remains to be
elucidated. Therefore, we performed a prospective,
blinded study monitoring nonimmunosuppressed, criti-
cally ill patients with severe sepsis for CMV reactivation
in blood and also in respiratory secretions. Active HSV
infection was evaluated as a potential cofactor of CMV
infection. The aim of this investigation was to assess the
impact of active CMV infection on survival, length of
ICU and hospital stay as well as on duration of mechani-
cal ventilation of non immunosuppressed patients with
severe sepsis.
Materials and methods
Patients
This prospective observational study was performed in
the surgical and the medical ICUs of the University
Hospital Tübingen between February 2004 and Septem-
ber 2006. All adult patients of the two ICUs were daily
screened for enrolment. The inclusion criteria were the
presence of severe sepsis as defined by the consensus
conference of the American College of Chest Physi-
cians/Society of Critical Care Medicine (ACCP/SCCM)
[19] and CMV seropositivity.
Exclusion criteria were the following: age younger than
18 years, pregnancy or breast feeding, duration of severe
s e p s i sf o rl o n g e rt h a n7 2h o u r s , antiviral treatment with
ganciclovir, valaciclovir, cidofovir, or foscarnet in the pre-
vious 7 days, and manifest immunosuppression because
of HIV infection, congenital defects, leukopenia <2,000/
μl, radiation or treatment with immunosuppressive sub-
stances within the last 6 months including prednisone,
rituximab, alemtuzumab, tacrolimus, sirolimus, ciclos-
porin, mycophenolic acid, azathioprine, anti-lymphocytic
or anti-IL6 antibodies.
Study protocol
The investigation was approved by the local ethics com-
mittee of the Faculty of Medicine, which waived the
need for informed consent. As soon as a patient fulfilled
the inclusion criterion of severe sepsis and had no
exclusion criterion present the first set of virological
examinations including CMV serology was performed
within the next three days
Patients having a positive anti-CMV IgG titer were
enrolled and further monitored for CMV reactivation
once a week until discharge from the University Hospi-
tal or death.
Clinicians were not aware of the virological results,
s i n c et h e yw e r ea s s e s s e di nas pecific internal database
applied for scientific purposes only. Ordering examina-
tions to look for CMV disease as well as the initiation
of antiviral treatment was left to the decision of the clin-
ician, independently of the study.
The following data were evaluated at enrolment: age,
gender, underlying disease requiring ICU treatment, the
type of infection and the organ dysfunction constituting
severe sepsis, presence of septic shock, the length of
stay in the ICU, duration of mechanical ventilation and
severity of illness and organ dysfunction as indicated by
the Simplified Acute Physiology Score (SAPS) II [20]
and the Sequential Organ Failure Assessment (SOFA)
scores. Additionally, the records of each patient were
reviewed for the presence of malignant disease, the
number of surgical procedures, and the number of red
blood cell units transfused during the current hospital
stay before enrolment. After enrolment it was registered
whether a CMV disease was diagnosed by the responsi-
ble clinicians. The study nurses collecting clinical data
were blinded for virological findings with the exception
of CMV serology, which was reported immediately.
The consequences of active CMV infection were long-
itudinally examined from enrolment until discharge or
death by assessing in-hospital mortality, length of stay
(LOS) in the ICU and in the hospital as well as time on
mechanical ventilator.
Virological assays
Samples were processed in the virological laboratory each
Monday and Thursday independently from the day
severe sepsis was diagnosed. The personnel performing
the virological examinations had no contact with patients
and no insight into clinical data. All data were fed into an
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blinding. Longitudinal CMV monitoring included virus
culture (human foreskin fibroblast monolayers) from tra-
cheal secretions, qualitative nested PCR targeting the
CMV IE1-Ex4 region [21] from leukocytes, plasma and
tracheal secretions, and quantification of CMV-DNA
(COBAS Amplicor CMV Monitor™ test, Roche Diagnos-
tics, Mannheim, Germany) from qualitative PCR-positive
plasma and tracheal secretion specimens. Experimental
details are given elsewhere [22,23]. In the first virological
examination CMV serology (anti-CMV IgG, anti-CMV
IgM enzyme immunoassays from Medac, Wedel,
Germany) was also assessed.
Moreover, respiratory secretions were examined by
real time PCR using primers and hybridization probes
derived from the DNA polymerase gene of HSV [24].
Vero cell monolayers were used to isolate HSV by cell
culture. All CMV and HSV strains isolated from micro-
culture were cryopreserved.
A status of viral latency was assigned if anti-CMV
immunoglobulin G (IgG) was present but the virus
could not be detected otherwise. Since earlier investiga-
tions had shown that healthy seropositive blood donors
deliver negative CMV PCR results from leukocytes and
plasma [25], CMV-DNA detection in plasma, leukocytes
or respiratory secretions or positive virus isolation was
defined as CMV reactivation.
Statistics
Baseline patient characteristics were summarized using
absolute frequencies and percentages with 95% confi-
dence interval (CI 95%) for nominal data, and median
(interquartile range (IQR)) for continuous data. The
baseline characteristics were compared between the
groups of patients with and without CMV reactivation
using Fisher’s Exact Test or Chi-Squared Test for nom-
inal variables and Wilcoxon-Test for continuous vari-
ables. Patients who died or were discharged within the
first 72 hours after study enrolment, were excluded from
data analysis. The two primary endpoints were the rate of
in-hospital mortality and length of stay in the ICU,
defined as days from study enrolment to death or dis-
charge from ICU. Secondary endpoints were duration of
hospital treatment and length of mechanical ventilation
defined accordingly. To evaluate the influence of CMV-
reactivation on these endpoints we conducted uni- and
multivariate Cox proportional-hazard regression analyses
adjusting for confounding factors. The analyses regarding
duration of hospital treatment and time on mechanical
ventilation (secondary endpoints) were based on the data
of the 55 surviving patients considering the following
variables: SAPS II at inclusion (Score points), ICU stay
before enrolment (days), septic shock at enrolment (yes/
no) and HSV detection (duration of hospital treatment)
and SAPS II, paO2/fiO2 ratio and presence of pneumonia
causing sepsis at enrolment (yes/no) as well as duration
of mechanical ventilation before inclusion (time on
mechanical ventilation). Continuous variables were gen-
erally used as linear factors, all others were used as
dichotomous factors in the regression models. Univariate
hazard ratios were calculated with 95% CI (not shown in
the tables) applying the Cox proportional-hazards model.
The modelling included testing for co-linearity, interac-
tions with the factor CMV reactivation, and proportional
hazard assumption for the risk factors. In a first step the
multivariate model considered all relevant risk factors,
which were in a second step optimized keeping only
CMV reactivation and those factors with a P < 0.05. Inci-
dence figures were created using the Kaplan-Meier esti-
mates. All P-values are two-sided. To additionally
consider time-dependency a landmark analysis was per-
f o r m e da tt h et i m ep o i n t0 ,D a y7a n dD a y1 4b a s e do n
the Cox-Regression. All statistical analyses were per-
formed with SAS System version 9.1 for Windows (SAS
Institute, Cary, NC, USA), and incidence figures were
created with SPSS version 17.0 for Windows (SPSS Inc.
Chicago, Illinois 60606, USA).
Results
Study population
A total of 129 patients were screened initially; 28 of them
were excluded because of negative CMV IgG serology, 2
suffered from lymphoma, and 1 had to be excluded due
to immunosuppressive chemotherapy. One patient was
excluded because of missing data. Thus a total of
97 patients were enrolled for further CMV monitoring.
Since six of them died and five were discharged from the
hospital within 72 hours, the data of 86 patients were
analysed; the majority of them (n = 64) were treated in
the two surgical ICUs. Baseline demographic characteris-
tics and clinical data of the 86 patients at enrolment are
presented in Table 1.
Virological examination results
In the 86 study patients on average (median) four sets of
samples for virological examination could be taken; 3.0
of them were collected during ICU stay, 3.0 on the
ward.
In 77 of the 86 patients both blood and tracheal secre-
tions could be obtained for virological testing; 9 patients
delivered only blood samples. Parameters of CMV reac-
tivation were found in 35 of the 86 patients (40.7%, CI
95%: 30.2 to 51.8) with severe sepsis. The distribution of
positive PCR results in the different compartments is
presented in Figure 1, indicating that in 13 of the 35
cases CMV reactivation was detected exclusively in the
lungs. On average (median) CMV reactivation occurred
21 days after enrolment into the study, becoming
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range 0 to 77 days) than in blood (median 24.5 days,
range 0 to 49 days), as shown in Figure 2. Interestingly,
HSV-DNA appeared even more frequently and mostly
earlier than CMV in respiratory secretions (Figures 1
and 2), yielding a positive PCR in 44 of the 86 study
patients. In patients with CMV reactivation (n = 35) the
rate of HSV detection added up to 65.7% (23 of 35)
compared to 41.2% (21 of 51) in the group where CMV
remained in the latent state (P = 0.025). Quantification
of CMV-DNA was performed in the 10 patients who
were tested positive in plasma by qualitative PCR. Four
of them showed plasma DNA levels beyond the detec-
tion limit of the COBAS Amplicor
® PCR system
(Roche) (600 copies/ml); in the other six patients the
CMV-DNA content in plasma was low with a peak
amount of 2,830 copies/ml on average (minimum 600,
maximum 1,608 copies/ml). CMV-DNA in leukocytes
was detected in 22 cases.
Consequences of CMV reactivation
The in-hospital mortality of all enrolled patients was 36.1%
(31 of 86) without any relevant difference between those
who showed CMV reactivation (37.1%, that is, 13 of 35; CI
95% 21.5 to 55.1) and those who did not (35.3%, that is, 18
of 51, CI 95% 22.4 to 50.0; P = 0.861) (Table 2). No CMV
disease was diagnosed by the responsible clinicians and
thus no treatment was initiated. Even when adjusted for
severity of illness, presence of septic shock, duration of
ICU stay before study enrolment and HSV reactivation,
in-hospital mortality of patients with CMV reactivation
was not increased (HR: 0.369, 95% CI: 0.136 to 1.005, P =
Table 1 Demography and underlying conditions of included patients (n = 86)
All patients Active CMV infection P-value
Yes No
n = 86 (100%) n = 35 (40.69%) n = 51 (59.31%)
Demographic data
Age (years)
a 68.0 (59 to 76) 68.0 (52 to 73) 69.0 (59 to 76) 0.237
Male sex (n (%)) 67 (77.9) 27 (77.1) 40 (78.4) 0.888
Surgical interventions requiring intensive care (n)
Neurosurgery 4 2 2
Abdominal surgery 33 14 19
Cardiovascular surgery 18 7 11
Other surgical procedures 9 6 3
All surgical interventions 64 29 35
Medical diseases requiring intensive care (n)
Liver disease 1 1 0
Coronary heart disease 2 0 2
Infections in the internal ICU 16 4 12
Other 3 1 2
All medical diseases 22 6 16 0.137
Infection causing severe sepsis (n (%))
b
Pneumonia 22 (25.9%) 11 (31.4%) 11 (22.0%) 0.329
Peritonitis 34 (40.5%) 12 (35.3%) 22 (44.0%) 0.425
Urinary tract infection 7 (8.5%) 4 (12.5%) 3 (6.0%) 0.263*
Catheter-associated bacteremia 6 (7.3%) 3 (9.4%) 3 (6.0%) 0.435*
Other 38 (55.1%) 18 (66.7%) 20 (47.6%) 0.121
Severity of illness at enrolment
Duration of ICU stay (days)
c,d 4.0 (2 to 9) 5.0 (2 to 11) 4.0 (2 to 9) 0.245
SAPS II Score
a 43.0 (36 to 51) 43.0 (33 to 47) 44.0 (37 to 33) 0.150
SOFA Score
a 8.0 (7 to 11) 8.0 (6 to 10) 9.0 (7 to 12) 0.060
Septic Shock present (n (%)) 55 (65.5%) 19 (57.6%) 36 (70.6%) 0.221
Transfusion of packed red cells
a,d 2.0 (0 to 6) 2.0 (0 to 5) 3.0 (0 to 8.5) 0.561
Duration of ventilation (days)
c,d 4.0 (2 to 9) 5.0 (2 to 11) 3.0 (2 to 9) 0.157
Surgical interventions
a,d 1.0 (1 to 2) 1.0 (1 to 2) 1.0 (1 to 2) 0.586
Horowitz index (paO2/fiO2) <200 (n (%)) 56 (65.9) 23 (67.7) 33 (64.7) 0.779
aMedian (interquartile range),
bAll infections sum up to more than 100%, because more than one infection could be noted in one patient,
cMedian (interquartile
range),
dDuring the actual hospital stay until enrolment into the study * Fisher’s exact test.
CMV, cytomegalovirus; SAPS, Simplified Acute Physiology Score; SOFA, Sequential Organ Failure Assessment score.
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effect on in-hospital mortality, we applied Cox regression
modelling at days 0, 7 and 14 (landmark analysis) consid-
ering the same factors thereby including HSV detection
according to its occurrence at the three time points. At
each time point, interaction between the tested factors was
proven to be not statistically significant. Results of the
optimized models are shown in Table 3. These data con-
firm that only SAPS II at inclusion influenced the in-hos-
pital mortality.
Focussing on increased morbidity an association with
CMV reactivation was observed. The LOS in the ICU
(30.0, interquartile range 14 to 48 vs. 12, interquartile
range 7 to 19 days; P < 0.001) as well as the duration of
hospital treatment (33.0, interquartile range 24 to 62 vs.
16.0 days, interquartile range 10 to 24; P < 0.001) and
the time on mechanical ventilation (22.0, interquartile
range 6 to 36 vs. 7.5 days, interquartile range 5 to 15.5;
P = 0.003) were significantly longer in patients with
CMV reactivation than in those without (Table 2).
T h ei m p a c to fC M Vr e a c t i v a t i o no nt h eL O Si nt h e
ICU was further elucidated by Cox regression again con-
sidering the factors mentioned above (Table 4). This
Cox model showed that CMV reactivation was clearly
associated with a longer ICU stay (HR 3.365, CI 95%
1.233 to 9.183; P = 0.018 and HR 2.441, CI 95% 1.011
to 5.897, P = 0.047, respectively, according to the opti-
mized model). Moreover, as for in-hospital mortality a
landmark analysis was performed based on the same
risk factors looking forward on the length of ICU stay
following days 0, 7 and 14 after enrolment, respectively
(Table 4). The SAPS II at inclusion became statistically
significant at all three time points and proved to be the
most important risk factor for prolonged ICU treatment.
In this landmark analysis only CMV reactivation at Day
7 was identified as a second risk factor with an indepen-
dent impact on the length of ICU stay following Day 7
after study inclusion (HR 2.853, CI 95% 1.003 to 8.117,
P = 0.049).
Moreover the surviving patients with CMV reactiva-
tion were at significantly higher risk for prolonged in-
hospital treatment as shown in Figure 3 (HR 3.3; CI
95% 1.78 to 6.25; P < 0.001). The adjusted proportional
hazard ratio for prolonged mechanical ventilation was
2.6 times higher in CMV reactivating patients than in
those who remained in a latent state (CI 95% 1.39 to
4.94, P < 0.001; optimized model; Figure 3). The
increased time of mechanical ventilation went along
with a significantly compromised pulmonary function in
patients with CMV reactivation. The Horowitz index
(paO2/fiO2 ratio) remained below 200 for six days
(interquartile range 1 to 17) in CMV reactivators com-
pared with three days in non-reactivators (interquartile
range 1 to 7, P = 0.038).
Discussion
This prospective, observational study demonstrated
CMV reactivation in 40.69% (35 of 86) of patients with
severe sepsis, despite the absence of other factors caus-
ing immunosuppression. This incidence of CMV reacti-
vation is amazingly consistent with the results of two
previous small German studies [12,16] and a more
recent retrospective investigation [26]. These authors
calculated a CMV reactivation rate of 45% in patients
with systemic inflammatory response syndrome or sepsis
[12], of 32% in patients with septic shock [16] and of
35% in cryopreserved plasma samples of long-term ICU
patients [26]. Thus, as proposed in the review by Osawa
and Singh [27], our prospectively assessed data clearly
identify septic patients as a defined subgroup in the ICU
population being at high risk for CMV reactivation.
A study examining 120 CMV-seropositive patients in
six US ICUs also revealed CMV reactivation in approxi-
mately one-third of the study group [13]. There is,
97 CMV-IgG-positive patients were monitored for CMV reactivation
11 of them died or were discharged within 72 h
86 patients were enrolled for data analysis
77 of them delivered blood and respiratory samples, 9 only blood samples
35 patients with CMV reactivation  (PCR) 51 patients without CMV reactivation
77 of them delivered blood and respiratory samples, 9 only blood samples
13 12x 10 13x   
in the lung
12x
in blood 
and lung
10x  
in blood
22x in leukocytes
10x also in plasma 
21x  active HSV infection 
of the lung
23x  active HSV infection 
of the lung
Figure 1 Positive CMV and HSV PCR results in leukocytes,
plasma, respiratory secretions of 97 patients.
Figure 2 CMV and HSV PCR in blood (CMV) and respiratory
secretions against time after study enrolment.
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co-workers [13] defined CMV reactivation exclusively
on the basis of findings in plasma, our study additionally
considered findings in leukocytes and respiratory secre-
tions. Referred to positive PCR results in plasma only,
the CMV reactivation rate in our study group was
clearly lower (11.6%) than in Limaye’s population.
A recent French investigation of 242 patients in a
medical ICU [9], which evaluated both blood and
respiratory samples indicated active CMV infection in
16% of the patients, which is less than half of the CMV
reactivation rate observed ino u rp a t i e n tp o p u l a t i o n .
This discrepancy can be attributed to differing CMV
detection methods, since the French results rely on
virus isolation from respiratory secretions. This techni-
que has been shown to be less sensitive than PCR-based
methods [18,27] as used in our study. Another explana-
tion might be a lower CMV risk of medical compared
with surgical ICU patients in general [14,27]. This
difference was also reflected in our own study group
with a CMV reactivation rate of 27.3% versus 45.3% (P
= 0.137) in medical and surgical patients, respectively.
In general any comparison of incidence rates for CMV
reactivation in critically ill patients is still compromised by
differences in the examined materials, by the use of var-
ious virological methods [14,26] and most importantly, by
differences between patient populations, which are not
reflected by usual scores as for example SAPS II or SOFA.
Our finding that HSV reactivation appeared in nearly
h a l fo ft h ep a t i e n t sa n dw a st h u sc l e a r l ym o r ef r e q u e n t
than CMV infection (Figure 2) agrees closely with the
data of Cook et al., who reported positive HSV and
CMV cultures in 23% and 15% of critically ill surgical
patients, respectively [11]. The frequent coincidence of
both herpes virus infections appeared quite similarly in
a small study group of 25 septic patients, where 6 of the
8 CMV-reactivating patients showed active HSV infec-
tion as well [16].
Table 2 Outcomes of included patients with and without CMV reactivation (n = 86)
All patients Active CMV infection P-value
Yes No
Parameter n n =8 6 n =3 5 n =5 1
Mortality (n (%))* 86 31 (36.1) 13 (37.1) 18 (35.3) 0.861
Length of stay in the ICU (days)
a, b * 86 16.5 (7 to 29) 30.0 (14 to 48) 12.0 (7 to 19) <0.001
Length of hospital stay (days)
a, b ** 86 22.5 (13 to 38) 33.0 (24 to 62) 16.0 (10 to 24) <0.001
Duration of mechanical ventilation (days)
a, b ** 82 12.0 (6 to 23) 22.0 (6 to 36) 7.5 (5 to 15.5) 0.003
aMedian (interquartile range);
bDefined as days after study enrolment.
*Primary endpoints; ** Secondary endpoints. CMV, cytomegalovirus.
Table 3 Cox regression analyses of factors associated with in-hospital mortality of the 86 included patients
Univariable analysis Multivariable analysis
Factor HR P-value HR 95% CI P-value
CMV reactivation 0.410 0.029 0.369 0.136 to 1.005 0.051
SAPS II at inclusion 1.062 <0.001 1.047 1.012 to 1.082 0.008
Septic Shock present 2.193 0.081 1.470 0.555 to 3.896 0.438
ICU stay before enrolment 1.010 0.298 1.022 0.999 to 1.046 0.058
HSV detection in respiratory secretions 1.539 0.268 1.546 0.687 to 3.480 0.292
Optimized model
CMV reactivation 0.496 0.215 to 1.145 0.101
SAPS II at inclusion 1.056 1.024 to 1.089 <0.001
Landmark analysis for Day 0, Day 7 and Day 14
Day 0 (86 patients, 12 of them with CMV reactivation)
CMV reactivation 0.983 0.974 1.005 0.347 to 2.911 0.993
SAPS II at inclusion 1.062 <0.001 1.062 1.030 to 1.096 <0.001
Day 7 (75 patients, 18 of them with CMV reactivation)
CMV reactivation 0.559 0.259 0.486 0.173 to 1.370 0.172
SAPS II at inclusion 1.063 0.001 1.064 1.027 to 1.102 <0.001
Day 14 (62 patients, 20 of them with CMV reactivation)
CMV reactivation 0.707 0.492 0.561 0.204 to 1.544 0.263
SAPS II at inclusion 1.065 0.003 1.067 1.026 to 1.111 0.001
CMV, cytomegalovirus; HR, hazard ratio; HSV, herpes simplex virus; SAPS, Sequential Organ Failure Assessment score.
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without CMV reactivation in our study group. Slight dif-
ferences between the two patient groups at baseline
regarding SAPS II, presence of septic shock and ICU stay
before enrolment suggest that selection bias might have
contributed to this finding. This limitation due to the
observational design of our study has to be taken into
account. To address this problem a Cox regression
adjusting for other potential risk factors was conducted.
But even this adjusted analysis showed no impact of
CMV reactivation on mortality (Table 3). This finding
may surprise at the first glance, because recent results
obtained in patients of French and US ICUs [9,13] as well
as our own earlier findings in surgical ICU patients [8]
suggested a higher mortality rate in CMV reactivators.
The main reason for this discrepancy might be the differ-
ence between the homogenous group of patients with
severe sepsis or septic shock presented here and the
more heterogeneous cohorts of ICU patients enrolled in
the other studies. This assumption is strongly corrobo-
rated, when our own previous results [8] are compared
with the actual findings. Although identical methods
were applied in the same setting, a remarkable effect of
CMV reactivation on mortality appeared in the mixed
group of seropositive surgical ICU patients of our former
study, but not in the current one exclusively focussing on
patients with severe sepsis. In this patient population,
severity and treatment of sepsis might be the most crucial
prognostic factors overriding potential effects of CMV
reactivation. Beyond this, the extent of the viral load
might strongly determine the effects on patient outcome,
as suggested by Limaye’s data [13] and also by the obser-
vations of Linssen and coworkers [28] in ICU patients
with HSV detection in respiratory secretions. This
assumption is strongly corroborated by the comparison
of our findings with Limaye’s results. Indeed, quantitative
PCR examinations delivered >1,000 copies per ml plasma
in 8% of our patients but in 20% of Limaye’sp a t i e n t s .
The higher incidence of plasma-DNAemia as well as the
higher level of plasma DNAemia observed by Limaye et
al. indicates that their patients developed a more serious
pattern of CMV reactivation than ours. Unequal treat-
ment modalities, such as transfusion of leukocyte-
depleted versus non-depleted blood products or different
catecholamine use [29] might have contributed to the dif-
ferent severity of CMV reactiva t i o na n d ,t h e r e b y ,t od i f -
ferent effects on in-hospital mortality.
Finally, it has to be mentioned, that a small effect of
CMV reactivation on mortality could have been over-
seen in our study due to the restricted number of exam-
ined patients. This is a major limitation of our study,
delivering a statistical power of less than 20% to detect
a 10% mortality difference between CMV reactivators
and non-reactivators.
CMV reactivation in our patients with severe sepsis
was accompanied by an increased LOS in the ICU (30.0,
interquartile range 14 to 48 vs. 12, interquartile range 7
to 19 days; P < 0.001), an extended time of in-hospital
treatment (33.0, interquartile range 24 to 62, vs. 16.0,
interquartile range 10 to 24 days; P < 0.001), and longer
Table 4 Cox regression analyses of factors associated with LOS in the ICU of the 86 included patients
Univariable analysis Multivariable analysis
Factor HR P-value HR 95% CI P-value
CMV reactivation 3.101 0.009 3.365 1.233 to 9.183 0.018
SAPS II at inclusion 1.065 <0.001 1.045 1.008 to 1.083 0.016
Septic Shock present 2.282 0.081 1.486 0.535 to 4.127 0.447
ICU stay before enrolment 1.006 0.577 1.020 0.996 to 1.044 0.104
HSV detection in respiratory secretions 1.302 0.501 1.338 0.595 to 3.013 0.481
Optimized model
CMV reactivation 2.441 1.011 to 5.897 0.047
SAPS II at inclusion 1.055 1.020 to 1.091 0.002
Landmark analysis for Day 0, Day 7 and Day 14
Day 0 (86 patients, 12 of them with CMV reactivation)
CMV reactivation 1.017 0.975 1.061 0.367 to 3.068 0.913
SAPS II at inclusion 1.065 <0.001 1.065 1.030 to 1.101 <0.001
Day 7 (64 patients, 16 of them with CMV reactivation)
CMV reactivation 2.274 0.112 2.853 1.003 to 8.117 0.049
SAPS II at inclusion 1.071 0.001 1.074 1.033 to 1.116 <0.001
Day 14 (47 patients, 17 of them with CMV reactivation)
CMV reactivation 2.109 0.164 2.538 0.861 to 7.479 0.091
SAPS II at inclusion 1.065 0.010 1.069 1.021 to 1.120 0.004
CI, confidence interval; CMV, cytomegalovirus; HR, hazard ratio; HSV, herpes simplex virus; LOS, length of stay; SAPS, Sequential Organ Failure Assessment score.
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Page 7 of 10time on the ventilator (22.0, interquartile range 6 to 36,
vs. 7.5 interquartile range 5 to 15.5 days; P =0 . 0 0 3 )
(Table 2). However, these data alone cannot give a clue
on the causality of CMV reactivation. The first reason is
that other risk factors rather than CMV reactivation
might have led to these enhanced treatment require-
ments. To address this point, we adjusted for the most
probably relevant factors using Cox regression (Table 4)
-- CMV reactivators (n = 35)
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Page 8 of 10but the number of included factors had to be limited to
four (beyond CMV reactivation) in order to avoid over-
fitting of the model [30], which is a limitation due to
sample size in our study. Nevertheless, the adjusted ana-
lysis confirmed the significant impact of CMV reactiva-
tion on the LOS in the ICU (primary endpoint) as well
as on the duration of in-hospital treatment and time on
mechanical ventilator (secondary endpoints). The other
result of the Cox regression, delineating HSV in contrast
to CMV not as a risk factor for prolonged ICU stay, fits
well with an earlier finding of Tuxen et al.[ 3 1 ] ,w h o
found no positive effect of acyclovir prophylaxis on the
LOS in ICU.
A second problem questioning the causative role of
CMV reactivation for prolonged intensive care treatment
is the potential confounding of LOS in the ICU with
opportunity to detect CMV. Unfortunately, a major lim-
itation of our study was that, due to logistical reasons,
CMV monitoring could not be continued after hospital
discharge of the patients. Therefore, in an attempt to
address this important issue, a landmark analysis was
also performed. This evaluation corroborated the associa-
tion of CMV reactivation with prolonged ICU stay when
we looked forward from Day 7 on the subsequent LOS.
Since this statistical approach allows control for time-
dependency of an effect it strengthened the assumption,
that CMV reactivation might be a true causative factor
contributing to extended treatment needs in patients
with severe sepsis. This suggestion is corroborated by the
findings in various mixed ICU populations [9,13,17,18]
and in one small population of 25 septic patients [16].
In severely immunosuppressed patients like in stem cell
transplantation, CMV pneumonia may lead to fatal out-
come. CMV disease was reported in single cases of acutely
ill, but otherwise immunocompetent, patients [32], but
such cases are rare and were not observed in this study.
Thus, other effects of CMV must be responsible for our
findings. Although the incidence of acute respiratory dis-
tress syndromes was not specifically addressed in our
study; impaired pulmonary function might be a possible
explanation. In patients with CMV reactivation, impair-
ment of the pulmonary gas exchange (paO2/fiO2 <200)
persisted significantly longer than in non-reactivating
patients (6.0, interquartile range 1 to 17 vs. 3.0, interquar-
tile range 1 to 7 days, P = 0.038. This result corresponds
well with the findings of Cook et al. [33] obtained in a
mouse model of CMV reactivation due to sepsis.
Nevertheless, one must keep in mind that the above
mentioned limitations of our study design do not allow
us to unequivocally establish the causative role of CMV
for extended treatment requirements. We cannot
exclude the possibility that CMV reactivation could be a
marker, rather than a cause, of serious illness.
As proposed by Osawa and Singh [27], a prospective
randomised multicenter trial of prophylactic antiviral
treatment might be the most goal-oriented method to
establish the causative role of CMV in adverse out-
comes. The fact that Limaye et al. observed a quantita-
tive association between CMV reactivation in terms of
plasma CMV-DNA levels and a combined endpoint
(death or ICU stay beyond day 30), whereas survival was
unaffected in our patients, who had much lower plasma
DNA levels, corroborates the importance of quantitative
examinations. A quantitative approach might offer the
chance to optimize the balance of potential harms and
benefits for participants of a randomized treatment trial.
Conclusions
In summary, our data indicate an independent correla-
tion between CMV reactivation and increased morbidity
in the well-defined group of nonimmunosuppressed
patients with severe sepsis, but CMV reactivation had
no impact on mortality in this group with low CMV-
DNA plasma levels. Thus, the potential harms and bene-
fits of antiviral treatment have to be weighed very cau-
tiously in patients with severe sepsis or septic shock.
Key messages
￿ Cytomegalovirus reactivation occurs in 40% of
non-immunosuppressed CMV-seropositive critically
ill patients with severe sepsis.
￿ Cytomegalovirus reactivation had no relevant impact
on mortality but was associated with increased length
of stay in the ICU and in the hospital.
￿ Cytomegalovirus reactivation was accompanied by
Herpes simplex infection in 65.7% of cases.
￿ Herpes simplex occurs earlier than CMV reactiva-
tion during severe sepsis.
Abbreviations
ACCP: American College of Chest Physicians; CI: confidence interval; CMV:
cytomegalovirus; HR: hazard ratio; HSV: herpes simplex virus; LOS: length of
stay; SAPS: Simplified Acute Physiology Score; SCCM: Society of Critical Care
Medicine; SOFA: Simplified Organ Failure Assessment.
Acknowledgements
The authors would like to acknowledge the excellent technical assistance of
Mrs. Andrea Baumann and Mrs. Elfriede Mikeler, who performed the
virological assays. We would also like to thank Mrs. Susanne Schwarze and
Mrs. Silvia Ziegler for collecting the clinical data.
Author details
1Klinik für Anaesthesiologie und Intensivmedizin, University Hospital of
Tübingen, Hoppe-Seyler-Str.03, 72076 Tübingen, Germany.
2Biostatistik-
Tübingen, Burgunderweg 36, 72070 Tübingen, Germany.
3Institut für
Medizinische Biometrie, Westbahnhofstr. 55, 72070 Tübingen, Germany.
4Institut für Medizinische Virologie und Epidemiologie der Viruskrankheiten,
University Hospital of Tübingen, Elfriede-Aulhorn-Str. 6, 72076 Tübingen,
Germany.
5Klinik für Innere Medizin, University Hospital of Tübingen, Otfried-
Müller-Straße 10, 72076 Tübingen, Germany.
6Inzlingerstr.3, 79639 Grenzach-
Wyhlen, Germany.
7Universitätsklinik für Allgemeine, Viszeral- und
Heininger et al. Critical Care 2011, 15:R77
http://ccforum.com/content/15/2/R77
Page 9 of 10Transplantationschirurgie, University Hospital of Tübingen, Hoppe-Seyler-
Str.03, 72076 Tübingen, Germany.
Authors’ contributions
AH designed and carried out the clinical study including data analysis, and
was the responsible first author, with an unrestricted grant as mentioned
above. HH recruited samples and is the corresponding author. IF was
responsible for statistical analysis. RB performed the virological analysis (HSV
PCR) and data analysis. RR recruited patients. FR was responsible for
discussion and the literature search. CM was responsible for statistical
analysis. GJ interpreted the data. AK and KU recruited patients and
contributed to the discussion. KH co-designed the virological study and was
responsible for virological monitoring, including the data analysis.
Competing interests
This study was sponsored in part by Roche Pharma AG, Grenzach-Wyhlen,
Germany. One of the co-authors (FR) was formerly employed by Roche
Pharma AG, whose product is active against CMV infection, which was
studied in the present work. There are no other competing interests.
Received: 3 August 2010 Revised: 10 February 2011
Accepted: 1 March 2011 Published: 1 March 2011
References
1. Munoz-Price LS, Slifkin M, Ruthazer R, Poutsiaka DD, Hadley S, Freeman R,
Rohrer R, Angelis M, Cooper J, Fairchild R, Barefoot L, Bloom J,
Fitzmaurice S, Snydman DR: The clinical impact of ganciclovir prophylaxis
on the occurrence of bacteremia in orthotopic liver transplant
recipients. Clin Infect Dis 2004, 39:1293-1299.
2. Kalil AC, Levitsky J, Lyden E, Stoner J, Freifeld AG: Meta-analysis: the
efficacy of strategies to prevent organ disease by cytomegalovirus in
solid organ transplant recipients. Ann Intern Med 2005, 143:870-880.
3. deJong MD, Galasso GJ, Gazzard B, Griffiths PD, Jabs DA, Kern ER,
Spector SA: Summary of the II International Symposium on
Cytomegalovirus. Antiviral Res 1998, 39:141-162.
4. Ljungman P, Griffiths P, Paya C: Definitions of cytomegalovirus
infection and disease in transplant recipients. Clin Infect Dis 2002,
34:1094-1097.
5. Sinclair J, Sissons P: Latency and reactivation of human cytomegalovirus.
J Gen Virol 2006, 87:1763-1779.
6. Boeckh M, Ljungman P: How we treat cytomegalovirus in hematopoietic
cell transplant recipients. Blood 2009, 113:5711-5719.
7. Gandhi MK, Khanna R: Human cytomegalovirus: clinical aspects, immune
regulation, and emerging treatments. Lancet Infect Dis 2004, 4:725-738.
8. Heininger A, Jahn G, Engel C, Notheisen T, Unertl K, Hamprecht K: Human
cytomegalovirus infections in nonimmunosuppressed critically ill
patients. Crit Care Med 2001, 29:541-547.
9. Chiche L, Forel JM, Roch A, Guervilly C, Pauly V, lardet-Servent J, Gainnier M,
Zandotti C, Papazian L: Active cytomegalovirus infection is common in
mechanically ventilated medical intensive care unit patients. Crit Care
Med 2009, 37:1850-1857.
10. Jaber S, Chanques G, Borry J, Souche B, Verdier R, Perrigault PF, Eledjam JJ:
Cytomegalovirus infection in critically ill patients: associated factors and
consequences. Chest 2005, 127:233-241.
11. Cook CH, Martin LC, Yenchar JK, Lahm MC, McGuinness B, Davies EA,
Ferguson RM: Occult herpes family viral infections are endemic in
critically ill surgical patients. Crit Care Med 2003, 31:1923-1929.
12. Kutza AS, Muhl E, Hackstein H, Kirchner H, Bein G: High incidence of active
cytomegalovirus infection among septic patients. Clin Infect Dis 1998,
26:1076-1082.
13. Limaye AP, Kirby KA, Rubenfeld GD, Leisenring WM, Bulger EM, Neff MJ,
Gibran NS, Huang ML, Santo Hayes TK, Corey L, Boeckh M:
Cytomegalovirus reactivation in critically ill immunocompetent patients.
JAMA 2008, 300:413-422.
14. Rafailidis PI, Mourtzoukou EG, Varbobitis IC, Falagas ME: Severe
cytomegalovirus infection in apparently immunocompetent patients: a
systematic review. Virol J 2008, 5:47.
15. Luyt CE, Combes A, Deback C, Aubriot-Lorton MH, Nieszkowska A,
Trouillet JL, Capron F, Agut H, Gibert C, Chastre J: Herpes simplex virus
lung infection in patients undergoing prolonged mechanical ventilation.
Am J Respir Crit Care Med 2007, 175:935-942.
16. von Muller L, Klemm A, Weiss M, Schneider M, Suger-Wiedeck H, Durmus N,
Hampl W, Mertens T: Active cytomegalovirus infection in patients with
septic shock. Emerg Infect Dis 2006, 12:1517-1522.
17. Cook CH, Yenchar JK, Kraner TO, Davies EA, Ferguson RM: Occult herpes
family viruses may increase mortality in critically ill surgical patients. Am
J Surg 1998, 176:357-360.
18. Kalil AC, Florescu DF: Prevalence and mortality associated with
cytomegalovirus infection in nonimmunosuppressed patients in the
intensive care unit. Crit Care Med 2009, 37:2350-2358.
19. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM,
Sibbald WJ: Definitions for sepsis and organ failure and guidelines for
the use of innovative therapies in sepsis. The ACCP/SCCM Consensus
Conference Committee. American College of Chest Physicians/Society of
Critical Care Medicine. Chest 1992, 101:1644-1655.
20. Le Gall Jr, Lemeshow S, Saulnier F: A new Simplified Acute Physiology
Score (SAPS II) based on a European/North American multicenter study.
JAMA 1993, 270:2957-2963.
21. Hamprecht K, Mikeler E, Jahn G: Semi-quantitative detection of
cytomegalovirus DNA from native serum and plasma by nested PCR:
influence of DNA extraction procedures. J Virol Methods 1997, 69:125-135.
22. Hamprecht K, Pfau M, Schaller HE, Jahn G, Middeldorp JM,
Rennekampff HO: Human cytomegalovirus infection of a severe-burn
patient: evidence for productive self-limited viral replication in blood
and lung. J Clin Microbiol 2005, 43:2534-2536.
23. Jacobi C, Riessen R, Schumacher U, Autenrieth IB, Jahn G, Gregor M,
Raible A, Hamprecht K: Life-threatening pneumonia caused by human
cytomegalovirus and Mycloplasma pneumoniae coinfection in a young,
immunocompetent patient. J Med Microbiol 2010, 59:980-983.
24. Burrows J, Nitsche A, Bayly B, Walker E, Higgins G, Kok T: Detection and
subtyping of Herpes simplex virus in clinical samples by LightCycler
PCR, enzyme immunoassay and cell culture. BMC Microbiol 2002, 2:12.
25. Hamprecht K, Steinmassl M, Einsele H, Jahn G: Discordant detection of
human cytomegalovirus DNA from peripheral blood mononuclear cells,
granulocytes and plasma: correlation to viremia and HCMV infection.
J Clin Virol 1998, 11:125-136.
26. Ziemann M, Sedemund-Adib B, Reiland P, Schmucker P, Hennig H:
Increased mortality in long-term intensive care patients with active
cytomegalovirus infection. Crit Care Med 2008, 36:3145-3150.
27. Osawa R, Singh N: Cytomegalovirus infection in critically ill patients: a
systematic review. Crit Care 2009, 13:R68.
28. Linssen CF, Jacobs JA, Stelma FF, van Mook WN, Teporten P, Vink C,
Drent M, Bruggeman CA, Smismans A: Herpes simplex virus load in
bronchoalveolar lavage fluid is related to poor outcome in critically ill
patients. Intensive Care Med 2008, 34:2202-2209.
29. Prosch S, Wendt CE, Reinke P, Priemer C, Oppert M, Kruger DH, Volk HD,
Docke WD: A novel link between stress and human cytomegalovirus
(HCMV) infection: sympathetic hyperactivity stimulates HCMV activation.
Virology 2000, 272:357-365.
30. Vittinghoff E, McCulloch CE: Relaxing the rule of ten events per variable
in logistic and Cox regression. Am J Epidemiol 2007, 165:710-718.
31. Tuxen DV, Wilson JW, Cade JF: Prevention of lower respiratory Herpes
simplex virus infection with acyclovir in patients with the adult
respiratory distress sndrome. Am Rev Respir Dis 1987, 136:402-405.
32. Heininger A, Vogel U, Aepinus C, Hamprecht K: Disseminated fatal human
cytomegalovirus disease after severe trauma. Crit Care Med 2000,
28:563-566.
33. Cook C, Zhang Y, Sedmak DD, Martin LC, Jewell S, Ferguson RM:
Pulmonary cytomegalovirus reactivation causes pathology in
immunocompetent mice. Crit Care Med 2006, 34:842-849.
doi:10.1186/cc10069
Cite this article as: Heininger et al.: Cytomegalovirus reactivation and
associated outcome of critically ill patients with severe sepsis. Critical
Care 2011 15:R77.
Heininger et al. Critical Care 2011, 15:R77
http://ccforum.com/content/15/2/R77
Page 10 of 10